Reported results
- Mipletamig achieved a 79% remission rate (CR or CRi) in 14 evaluable TP53-mutated AML patients.
- Ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine proceeded to allogeneic stem cell transplantation.
- Cash and cash equivalents totaled $8.3 million as of September 30, 2026.
- Net loss for the third quarter of 2026 was $6.5 million.
- The company completed a warrant inducement and private placement in August 2026 that generated gross proceeds of approximately $4.5 million.
Guidance
- Study completion for the RAINIER trial is targeted by year-end 2026.
- Regulatory interaction for mipletamig is planned for the first half of 2027.
- Two preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
